New research publications: November 2025

Each month, our R.E.D. blog showcases the activities of our research and education network and the innovation and collaboration that drives our scientific community forward. Included in these activities are the peer-reviewed publications in academic journals that are a main avenue for researchers to share their scientific findings. With a focus on methodology and a rigorous review process prior to publication, these publications are recognized as credible and reliable sources of scientific information.

This blog – part of a reoccurring monthly recap – provides an overview of the latest research publications that have been authored by Canadian Blood Services staff scientists in discovery, development and donation policy & studies; adjunct scientists; medical experts and trainees; and/or resulting from supported projects or partnerships.

Visit blood.ca to learn more about Our Research Team and to search our full publication database (updated annually).

By the numbers

For the month of November, we are reporting a total of 12 peer-reviewed research articles indicated by research focus area:

Discovery (3): These publications showcase a tribute to a leader in the field of cryobiology, new insights on the genetics of red blood cells‘ resiliency, and a correction on data from previous plasma protein inhibitor research.

Donation policy & studies (4): This research provides insights into pandemic antibody surveillance and antimicrobial resistance.

Adjunct scientists (1): This publication shows that dried plasma remains effective and stable in extreme cold.

Other Canadian Blood Services affiliations (4): These publications highlight better transfusion education, targeted therapies for rare blood disorders, cell and gene therapy as well as cord blood banking economics.

Where we published

Our research appeared in 10 journals, including the American Journal of Epidemiology, Journal of Biotechnology and BMJ Open.

Spotlight on select publications

• From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials.
  
  “This commentary makes the case that congenital factor V deficiency, an ultra-rare bleeding disorder still managed primarily with plasma and platelets, is ready for targeted therapies. We outline a pragmatic roadmap from bench to first-in-human trials, drawing on lessons from the development of factor X and XIII therapeutics, existing patient registries, and regulatory incentives for rare diseases.
  
  Our goal is to catalyze partnerships between clinicians, patients, and industry so that factor V–deficient patients can access the same therapeutic advances available for other coagulation disorders."
  
  Dr. Sheharyar Raza, Canadian Blood Services medical officer & transfusion medicine specialist

• Development and validation of a pediatric transfusion medicine education assessment tool.
  
  “In 2024-2025, the transfusion medicine education program Transfusion Camp was adapted to include a pediatric-focused curriculum. With support from Canadian Blood Services, this Pilot Pediatric Transfusion Camp curriculum was delivered under the broader Transfusion Camp framework to pediatric anesthesia and pediatric hematology/oncology trainees at the University of Toronto, Université de Montréal, University of Calgary, and University of British Columbia to address knowledge gaps about transfusion practices in this sub-population of patients. To assess the knowledge uptake gained through the program, authors developed a new Pediatric Transfusion Knowledge Test. This publication describes the test development and validation process.”
  
  Casey Kapitany, Canadian Blood Services, on behalf of the Transfusion Camp Coordinating Office

Our November publications list

This list includes any articles published this month, as well as those that have been e-collected or e-published on PubMed that have not previously appeared in our monthly publications list*.

• Development and validation of a pediatric transfusion medicine education assessment tool.
  Zuna I, Lin Y, Haspel R, Walsh CM, Bone JN, Kapitany C, Lieberman L, Skelton T. Transfusion. 2025 Nov 4. doi: 10.1111/trf.18477. PMID: 41187003

• The impact of statistical adjustment for assay performance on inferences from SARS-CoV-2 serological surveillance studies.
  Chen J, Yu Y, O'Brien SF, Charlton CL, Drews SJ, Heffernan JM, Smith AM, Nakagama Y, Kido Y, Buckeridge DL, Russell WA. Am J Epidemiol. 2025 Nov 4;194(11):3373-3381. doi: 10.1093/aje/kwaf157.PMID: 40699212

• Corrigendum to "Substitution of reactive centre loop residues from C1 esterase inhibitor increases the inhibitory specificity of alpha-1 antitrypsin for plasma kallikrein" [J. Biotechnol. 405 (2025) 205-214].
  Sivananthan S, Ahmed SA, Baig AM, Bhakta V, Sheffield WP. J Biotechnol. 2025 Nov 8;409:182. doi: 10.1016/j.jbiotec.2025.11.003. PMID: 41207264

• Comparability of Canadian SARS-CoV-2 seroprevalence estimates with statistical adjustment for socio-demographic representation.
  Yu Y, Chen J, Knight MJ, O'Brien SF, Buckeridge DL, Charlton CL, Russell WA. Can J Public Health. 2025 Nov 10. doi: 10.17269/s41997-025-01128-z. PMID: 41214282

• From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials.
  Jacobs JW, Raza S, Figueroa Villalba CA, Adkins BD, Walker SC, Booth GS, Sharma D, Wheeler AP. Semin Thromb Hemost. 2025 Nov 10. doi: 10.1055/a-2735-1659. PMID: 41167601

• COVID-19 antibody testing study: a nested substudy within Alberta's Tomorrow Project (ATP) in Alberta, Canada.
  Nejatinamini S, Charlton C, Harman S, Kanji JN, Kellner JD, Lines K, Murdoch K, Powell W, Roberts J, Rosner W, Shen-Tu G, Tipples G, Xu JY, Vena JE. BMJ Open. 2025 Nov 13;15(11):e101336. doi: 10.1136/bmjopen-2025-101336.PMID: 41248356

• A systematic scoping review of published economic analyses of public cord blood banking: Is it time to reassess?
  Allan LE, Shorr R, Seftel M, Villeneuve PJA. Transfusion. 2025 Nov 14. doi: 10.1111/trf.18483. PMID: 41235940

• Dried plasma retains hemostatic function and thermal stability during Arctic military operations.
  Singh K, Shoara AA, Peng HT, Prifti V, Moes K, McGuinness C, Bonnici T, Shiu M, Selvakumar SC, Andrisani P, Dion PM, Miller D, Vuong S, Kretz CA, Wallace PJ, Rhind SG, Sullivan-Kwantes W, Beckett AN. Transfusion. 2025 Nov 16. doi: 10.1111/trf.70003. PMID: 41241851

• Genetic architecture of the murine red blood cell proteome reveals central role of hemoglobin beta cysteine 93 in maintaining redox balance.
  Keele GR, Dzieciatkowska M, Hay AM, Vincent M, O'Connor C, Stephenson D, Reisz JA, Nemkov T, Hansen KC, Page GP, Zimring JC, Churchill GA, D'Alessandro A. Cell Genom. 2025 Nov 19:101069. doi: 10.1016/j.xgen.2025.101069. PMID: 41265446

• In memoriam: James Lovelock (1919-2022) - A scientific life in cryobiology and beyond.
  Hemmatibardehshahi S, Phan C, Acker JP. Cryobiology. 2025 Nov 19:105547. doi: 10.1016/j.cryobiol.2025.105547. PMID: 41266191

• Surveillance of Antimicrobial Resistance in Neisseria gonorrhoeae in Alberta from 2016-2022.
  Walsh TM, Plitt SS, Dingle TC, Charlton CL. Antibiotics (Basel). 2025 Nov 6;14(11):1119. doi: 10.3390/antibiotics14111119.PMID: 41301614

• Genetic findings of potential donor origin in cells used for cell and gene therapy: Recommendations from the World Marrow Donor Association (WMDA).
  Pryce A, Cody M, Madbouly A, van Eerden E, Machin LL, Stefanski HE, Hatton D, Anthias C, Hernandez D, Bannon S, Mengling T, Allan DS. Transplant Cell Ther. 2025 Nov 26:S2666-6367(25)01591-X. doi: 10.1016/j.jtct.2025.11.016.

*Items in this list are identified using a process that relies on the PubMed database. While we aim to capture all relevant research articles, limitations in database indexing and search parameters may occasionally cause articles to be missed. If you are the author of an article that you believe has been missed from this monthly list, we encourage you to contact us at centreforinnovation@blood.ca to inquire.

We are proud of the remarkable work being done across Canadian Blood Services’ network. Stay tuned for more blog posts as we continue to advance scientific discovery and innovation for the Canadian blood system.

Canadian Blood Services – Driving world-class innovation

Through discovery, development and applied research, Canadian Blood Services drives world-class innovation in blood transfusion, cellular therapy and transplantation—bringing clarity and insight to an increasingly complex healthcare future. Our dedicated research team and extended network of partners engage in exploratory and applied research to create new knowledge, inform and enhance best practices, contribute to the development of new services and technologies, and build capacity through training and collaboration. Find out more about our research impact. 

The opinions reflected in this post are those of the author and do not necessarily reflect the opinions of Canadian Blood Services nor do they reflect the views of Health Canada or any other funding agency.